An innovative, first-in-class oral lipid-lowering medication is Bempedoic acid (BA). Since the end of 2020, BA has been commercialized throughout Europe as an add-on therapy for patients with high/very high cardiovascular risk who are not reaching LDL-C goals with existing lipid-lowering medications. BA has received approval from both the European Medicines Agency and the Food and Drug Administration. Italian lipid management experts recently met to discuss several unresolved issues regarding the therapeutic relevance of BA features and BA-related practical clinical issues. The panel agreed to have its thoughts collected in a ten-question format.